Topokine Therapeutics is a clinical-stage biotechnology company developing topical medications for non-invasive contouring of the face and body. The company’s lead program, XAF5 Ointment, is a topical adipomodulatory product in Phase 2 clinical development for two indications: local reduction of excess eyelid fat (steatoblepharon) and reduction of excess submental fat (“double chin”). Topokine’s pipeline also includes TAT4, a topical “filler” therapy to increase local tissue volume.